COMPERA 2.0: a refined four-stratum risk assessment model for pulmonary arterial hypertension. Issue 1 (7th July 2022)

• Record Type: Journal Article
• Authors: Hoeper, Marius M.; Pausch, Christine; Olsson, Karen M.; Huscher, Doerte; Pittrow, David; Grünig, Ekkehard; Staehler, Gerd; Vizza, Carmine Dario; Gall, Henning; Distler, Oliver; Opitz, Christian; Gibbs, J. Simon R.; Delcroix, Marion; Ghofrani, H. Ardeschir; Park, Da-Hee; Ewert, Ralf; Kaemmerer, Harald; Kabitz, Hans-Joachim; Skowasch, Dirk; Behr, Juergen; Milger, Katrin; Halank, Michael; Wilkens, Heinrike; Seyfarth, Hans-Jürgen; Held, Matthias; Dumitrescu, Daniel; Tsangaris, Iraklis; Vonk-Noordegraaf, Anton; Ulrich, Silvia; Klose, Hans; Claussen, Martin; Lange, Tobias J.; Rosenkranz, Stephan;
• Is Part Of: European respiratory journal. Volume 60:Issue 1(2022)
• Publication Date: 2022-07-07
• Subjects: Respiratory organs -- Diseases -- Periodicals; Respiration -- Periodicals; 616.2
• DOI: 10.1183/13993003.02311-2021
• Languages: English
• ISSNs: 0903-1936

Abstract

Background: Risk stratification plays an essential role in the management of patients with pulmonary arterial hypertension (PAH). The current European guidelines propose a three-stratum model to categorise risk as low, intermediate or high, based on the expected 1-year mortality. However, with this model, most patients are categorised as intermediate risk. We investigated a modified approach based on four risk categories, with intermediate risk subdivided into intermediate-low and intermediate-high risk. Methods: We analysed data from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA), a European pulmonary hypertension registry, and calculated risk at diagnosis and first follow-up based on World Health Organization functional class, 6-min walk distance (6MWD) and serum levels of brain natriuretic peptide (BNP) or N-terminal pro-BNP (NT-proBNP), using refined cut-off values. Survival was assessed using Kaplan–Meier analyses, log-rank testing and Cox proportional hazards models. Results: Data from 1655 patients with PAH were analysed. Using the three-stratum model, most patients were classified as intermediate risk (76.0% at baseline and 63.9% at first follow-up). The refined four-stratum risk model yielded a more nuanced separation and predicted long-term survival, especially at follow-up assessment. Changes in risk from baseline to follow-up were observed in 31.1% of the patients with the three-stratum model and in 49.2% with the four-stratum model. These changes, including those between the intermediate-low and intermediate-high strata, were associated with changes in long-term mortality risk. Conclusions: Modified risk stratification using a four-stratum model based on refined cut-off levels for functional class, 6MWD and BNP/NT-proBNP was more sensitive to prognostically relevant changes in risk than the original three-stratum model. COMPERA 2.0, a four-stratum risk assessment model based on refined cut-off levels for functional class, 6MWD and BNP/NT-proBNP was more sensitive to prognostically significant changes in risk than the original three-stratum model https://bit.ly/3mzPKjA